Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered virotherapies and related cell-based delivery platforms for cancer treatment. The company is advancing product candidates such as CLD-101 and CLD-201, while also building the manufacturing, regulatory, and intellectual property infrastructure needed to support future clinical and commercial development. It currently has no product sales and remains dependent on external financing to fund research, development, and operations. Calidi is headquartered in the United States and also operates through subsidiaries in Germany and Australia to support parts of its development and trial activities.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueEngineered virus-based cancer therapeutics designed to attack tumors and stimulate anti-tumor immune responses.
Cell therapy approaches used to deliver therapeutic payloads and improve targeting of tumor sites.
Research, toxicology, trial execution, and regulatory work required to advance product candidates.
Customers
Calidi does not currently sell commercial products, so its near-term 'customers' are primarily research partners, clinical investigators, contract manufacturers, and potential future licensing or commercialization partners. In a commercial setting, the company’s therapies would ultimately be used by oncology physicians and hospitals treating patients with solid tumors or other cancers targeted by its programs. The company also relies on universities and licensors for access to underlying technology, including agreements with Northwestern University, City of Hope, and the University of Chicago. If its programs progress successfully, pharmaceutical partners would be important buyers of development rights, manufacturing support, or regional commercialization rights.
Hospitals, investigators, and trial vendors that support the testing of CLD-101 and CLD-201 in patients.
Specialty manufacturers and suppliers that produce clinical-grade viral and cell therapy materials for development programs.
Universities and research institutions that license foundational IP and may receive contingent payments if programs advance.
Biopharma companies that could license, co-develop, or commercialize Calidi’s candidates after clinical validation.
Strategy
Calidi’s strategy is centered on advancing its current and future product candidates through preclinical and clinical development while preserving enough capital to remain a going concern. The company is also building the manufacturing, regulatory, and intellectual property capabilities needed to support eventual approval and commercialization. Because it has no product revenue, partnering is strategically important: management expects collaboration agreements, strategic alliances, or licensing arrangements to help fund development and reduce the burden of building a full commercial infrastructure alone. In the near term, the company’s success depends on clinical progress, capital raises, and maintaining access to specialized manufacturing and trial execution capabilities.
The company has stated it does not have sufficient cash to support operations for at least one year and needs funding to continue development.
Clinical progress is required to create value, support regulatory filings, and eventually enable commercialization.
Third-party partnerships could provide non-dilutive funding and commercialization capabilities that Calidi does not yet have.
Geography
Calidi is based in the United States, where its principal executive and administrative offices and laboratory facility are located in San Diego. The company also operates through wholly owned subsidiaries in Germany and Australia, reflecting a development footprint that extends beyond the U.S. for research, staffing, and clinical trial execution. Management specifically noted foreign vendors and employees in Europe, particularly Germany, and a subsidiary in Australia formed to support a portion of planned clinical trial activities for the SNV1 program. Because the company is still pre-commercial, geography matters mainly through where R&D work is performed, where trial activity is conducted, and where foreign-currency costs are incurred.
Risks
Calidi faces substantial going-concern and financing risk because it has no product revenue and expects continuing operating losses as it funds research, trials, and regulatory work. Clinical-stage biotechnology companies also face high technical and regulatory risk: product candidates may fail in preclinical testing, clinical trials, or regulatory review, which would reduce or eliminate future value. The company is exposed to manufacturing and supply-chain risk because it depends on third-party vendors for clinical drug product and supply, and those arrangements can be costly or disrupted. It also has foreign operating exposure through Germany and Australia, which introduces currency, staffing, and cross-border execution risk, while broader market conditions can affect its ability to raise capital on acceptable terms.
Management disclosed that current cash is not sufficient to support operations for at least one year and that substantial additional funding is required.
Exposure: Corporate funding and operating continuity
The company’s value depends on advancing unapproved product candidates through preclinical and clinical stages, where failure rates are high.
Without product revenue, the company must fund operations through equity offerings, debt, or partnerships, which may not be available on favorable terms.
Clinical drug product and supply are sourced from vendors, making timelines and costs vulnerable to third-party performance.
Exposure: Clinical supply chain
Operations in Germany and Australia and use of European vendors create exposure to exchange-rate and cross-border execution issues.
Accounting
Judgemental itemsManagement disclosed substantial doubt about the company’s ability to continue as a going concern, which is central to interpreting the financial statements.
Impact: Affects liquidity analysis, valuation, and financing assumptions
As a clinical-stage biotech, most spending is expensed as incurred, driving losses and making period comparisons sensitive to trial timing.
Impact: Affects operating loss and quarterly volatility
The San Diego lease and other operating leases create recognized liabilities and future payment obligations.
Impact: Affects balance sheet liabilities and cash commitment disclosure
License agreements with universities may require future contingent payments if specified milestones are reached.
Impact: Affects contingent liability disclosure and future cash outflows
Similar listed companies
Publicly listed companies with a comparable business focus.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Last updated: 24/09/2026